NCT01646489View on ClinicalTrials.gov

Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

June 30, 2012

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
Hepatitis CChronic Hepatitis C
Interventions
DRUG

Miravirsen sodium

Miravirsen 7 mg/kg to be administered as single subcutaneous injections for a total of 5 doses over a 5 week treatment period.

DRUG

Telaprevir

Telaprevir 750 mg to be administered as single and multiple oral doses over two 7 day treatment periods.

Trial Locations (1)

53095

Spaulding Clinical Research, West Bend

All Listed Sponsors
lead

Santaris Pharma A/S

INDUSTRY

NCT01646489 - Drug Interaction Study to Assess the Effect of Co-Administered Miravirsen and Telaprevir in Healthy Subjects | Biotech Hunter | Biotech Hunter